Dow Down0.32% Nasdaq Down0.62%

Gilead Sciences Inc. (GILD)

-NasdaqGS
88.21 Down 8.79(9.06%) Apr 29, 4:00PM EDT
|After Hours : 88.37 Up 0.16 (0.18%) Apr 29, 7:57PM EDT
ProfileGet Profile for:
Gilead Sciences Inc.
333 Lakeside Drive
Foster City, CA 94404
United States - Map
Phone: 650-574-3000
Fax: 650-578-9264
Website: http://www.gilead.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:8,000

Business Summary 

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Gilead Sciences Inc.

Corporate Governance 
Gilead Sciences Inc.’s ISS Governance QuickScore as of Apr 1, 2016 is 4. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 4; Compensation: 6.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Dr. John C. Martin Ph.D., 64
Exec. Chairman
5.77M164.52M
Dr. John F. Milligan Ph.D., 55
Chief Exec. Officer, Pres and Director
2.99M74.08M
Ms. Robin L. Washington , 53
Chief Financial Officer and Exec. VP
1.95M3.93M
Dr. Norbert W. Bischofberger Ph.D., 60
Chief Scientific Officer and Exec. VP of R&D
2.28M72.16M
Mr. Gregg H. Alton , 50
Exec. VP of Corp. & Medical Affairs
2.03M14.64M
Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders